MCRB Description — Seres Therapeutics Inc

Seres Therapeutics is a microbiome therapeutics platform company developing live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified Firmicutes spores. Using Co.'s microbiome therapeutics platform, Co. is also developing SER-287 and SER-301 to treat ulcerative colitis. Co. evaluates microbiome pharmacokinetic and pharmacodynamic data from across its clinical and pre-clinical portfolios using its reverse translation microbiome therapeutics capabilities to conduct research on various indications, including inflammatory and immune diseases, cancer, and metabolic diseases.

Company Name: 
Seres Therapeutics Inc
Drugs & Pharmaceuticals
Number of ETFs Holding MCRB: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   MCRB Weight   MCRB Amount 
 VTI   0.00%   $18,869,785         
 XBI   0.21%   $17,016,657         
 IWM   0.02%   $10,950,298         
 VXF   0.01%   $8,512,348         
 IWO   0.04%   $3,707,488         
 VHT   0.01%   $2,351,570         
 PTH   0.87%   $2,029,248         
 DWAS   0.37%   $1,574,158         
 VTWO   0.02%   $1,159,360         
 IWC   0.11%   $991,992         
List of all 26 ETFs holding MCRB »
Quotes delayed 20 minutes

Email EnvelopeFree MCRB Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
84th percentile
(ranked higher than approx. 84% of all stocks covered)

Analysts Forecast:
MCRB Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding MCRB | Seres Therapeutics Inc | ETF Channel |

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.